Brazil Suspends Clinical Trials of Chinese Covid Vaccine Due to "Adverse Incident"
Brazil's health regulator said Monday it had suspended clinical trials of a Chinese-developed Covid-19 vaccine after an "adverse incident" involving a volunteer recipient.
Rio de Janeiro: Brazil's health regulator said Monday it had suspended clinical trials of a Chinese-developed Covid-19 vaccine after an "adverse incident" involving a volunteer recipient, a blow for one of the most advanced vaccine candidates.
The regulator, Anvisa, said in a statement that it had "ruled to interrupt the clinical trial of the CoronaVac vaccine after a serious adverse incident" on October 29.
It said it could not give details on what happened because of privacy regulations, but that such incidents included death, potentially fatal side effects, serious disability, hospitalization, birth defects and other "clinically significant events."
Original News: World | Agence France-Presse
(Except for the headline, this story has not been edited by Scrabbl staff and is published from a syndicated feed.)
